Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- TECOS Shows Sitagliptin Neutrality vis-à-vis MACE in High-Risk CAD
- ADA: Sitagliptin Shows No Major Adverse CV Effects in T2DM, CVD
- Primary Endpoint of Cardiovascular Safety Met for Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
- Heart Failure Risk in Type 2 Diabetics on Oral Glucose-Lowering Medications
Disclosure statements are available on the authors' profiles: